Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business

      BioLife Solutions New Logo 2021 (PRNewsfoto/BioLife Solutions, Inc.)

      News provided by

      BioLife Solutions, Inc.

      Aug 08, 2023, 16:03 ET

      Share this article

      Share this article


      Committed to Divesting Stirling Ultracold and Custom Biogenic Systems by End of 2023

      Conference call begins at 4:30 p.m. Eastern time today 

      BOTHELL, Wash., Aug. 8, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced financial results for the second quarter and six months of 2023 and updated guidance for the full year 2023. Management is also providing a first half 2023 financial profile of certain pro forma financial metrics excluding Stirling Ultracold (Stirling) and Custom Biogenic Systems (CBS) freezer assets, both of which management intends to divest by December 31, 2023.

      Mike Rice, Chairman and CEO, commented, "Subsequent to the end of the second quarter 2023, after considering other strategic alternatives, management and the board of directors have determined that divesting our Stirling and CBS freezer assets would optimize the performance of our product portfolio by focusing on recurring higher margin streams and create the most shareholder value.  We made significant progress to achieve this objective and based on the level of interest and the feedback we have received so far; we are fully committed to starting 2024 without the impact of the freezer product lines.  We continue to appreciate the value of the related IP, products and teams, and believe a buyer or buyers will materialize that can continue to provide global access to these innovative products in a cost structure that fits their financial requirements."

      Management anticipates reclassifying the freezer product lines as Assets Held for Sale and Discontinued Operations in the second half of 2023 when the accounting criteria are met.

      To assist investors with understanding the positive impacts of these potential divestitures, the Company is now providing certain unaudited pro forma financial information had the divestitures occurred on January 1, 2023. This unaudited pro forma financial information is presented for informational purposes only and is not intended to represent or be indicative of the results had the divestiture occurred at an earlier date and should not be taken as representative of our future consolidated results of operations or financial condition.  Preparation of this certain unaudited pro forma financial information required management to make certain judgments and estimates to determine the adjustments based on information currently available, which is subject to management's ongoing process as part of the divestiture transaction. Actual results may differ from the assumptions used to present this certain unaudited pro forma financial information.

      The following table illustrates BioLife's financial results for the first half of 2023 excluding revenues and costs associated with our freezer assets.


      Reported Results


      Pro Forma Results Excluding Freezers


      Q2 2023 YTD


      Q2 2023 YTD

      Revenue

      $                   77,210


      $                   51,548

      Gross Margin

      32 %


      48 %

      Adjusted Gross Margin

      35 %


      52 %

      Adjusted EBITDA(1)

      $                   (2,247)


      $              8,216 - 9,216

      Adjusted EBITDA %(1)

      4 %


      16 - 18 %


      (1)\Adjusted EBITDA (non-GAAP) for the pro forma results excluding freezers was calculated utilizing certain estimates and judgments by management utilizing the most updated information available at this time. Given that estimated results may vary, a range of Adjusted EBITDA as a percentage of revenue was provided. Due to the level of estimation required, actual results may differ from assumptions used to present this pro forma information.

      Mike Rice, Chairman and CEO, further commented, "We are confident the portfolio of high value recurring products and services, and expected strong resulting financial profile, after the divestiture of the freezer businesses, will better align BioLife to the attractive growth and profitability opportunities for a key supplier to the CGT industry. We sell critical CGT products that are sole-sourced from BioLife. These are not one-time buys but rather consumables that need to be replenished. We have a strong brand and track record with limited competitive substitutes. Our CGT customers participate in an emerging class of therapeutic modalities that are just now becoming real, and we naturally expect demand for our products to increase as they progress their programs.  The reality is just that right now, the economy is tighter, and the participants in this ecosystem all want to reduce cash burn."

      Sustained catalysts that we expect to drive BioLife growth due to a significant increase in the number of manufactured doses include:

      • Approvals of new cell and gene therapies
      • Additional approvals of commercial CGT in new geographies
      • Additional approvals of CGT in new indications
      • Migration of commercial therapies to first or second-line treatment
      • An eventual transition to allogeneic therapies

      In the near term, results continue to be impacted by constraints pressuring the broader bioprocessing sector including the following factors:

      • Macro headwinds of global economic uncertainty causing reduced biotech spending across our customer base not only for capital equipment but also consumables. We believe these are more transitory, and similar to the outlooks of our bioprocessing peers, anticipate a recovery in 2024 as customer supply chain dynamics improve.
      • Cell processing revenue concentration and lumpiness caused by:
        • Destocking by our largest direct customer compared to prior year period.
        • Slowed growth from our largest distributor compared to prior period, caused by several of their downstream clinical customers having to complete validation of a new media product final container we introduced to mitigate supply chain shortages.
      • Several clinical CGT customers' reduced spending due to reduced clinical trial activity (trial early termination, pauses between phases and delayed patient enrollment).
      • Manufacturing bottlenecks at some CGT customers or their related CMOs due to capacity constraints and/or shortages of raw materials from other suppliers.

      Troy Wichterman, Chief Financial Officer, commented, "While near term results are disappointing, we remain confident in the mid- and long-term growth potential for BioLife and our ability to generate cash flows from operations post our freezer divestitures."

      Second Quarter 2023 Customer Highlights

      New Customer Acquisition

      Platform/Solution

      Q1 2023

      Q2 2023

      1H2023

      FY2022

      Biopreservation Media

      9

      19

      28

      69

      Sexton Cell Processing

      8

      10

      18

      33

      SciSafe® Storage Services

      22

      21

      43

      99

      Thaw

      5

      6

      11

      35

      evo® Cold Chain

      17

      17

      34

      43

      Cryogenic Freezers

      15

      13

      28

      82

      ULT Freezers

      121

      102

      223

      461

      TOTAL

      197

      188

      385

      822

      • Gained nearly 200 new customers.
      • Processed 20 new USA Master File cross references for our cell processing solutions. We estimate that over 800 total global clinical applications have our BioLife Solutions or Sexton cell processing solutions embedded in their manufacturing processes.
      • evo cold chain management shipments of cell and gene therapies totaled 3,019 in Q2 2023

      Second Quarter 2023 Financial Results

      BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP). A reconciliation of GAAP to non-GAAP metrics appears at the end of this news release.

      REVENUE

      • Total revenue for the second quarter of 2023 was $39.5 million, a decrease of $1.0 million, or 3%, from $40.5 million for the second quarter of 2022. There was no COVID-19 related revenue in the second quarter of 2023. Ex-COVID related revenue growth for the second quarter of 2023 was 7%.
        • Cell Processing platform revenue was $18.7 million, up $3.3 million, or 22%, over the same period in 2022. Biopreservation media growth was 21%.
        • Freezers and Thaw Systems platform revenue was $13.9 million, down $4.8 million, or 26%, over the same period in 2022. Ex-COVID related revenue was down $4.1 million, or 23%, over the same period in 2022.
        • Storage and Storage Services platform revenue was $6.9 million, up $0.4 million, or 7%, over the same period in 2022. Ex-COVID related revenue growth was $3.4 million, or 94%, over the same period in 2022.
      • Total revenue for the six months ended June 30, 2023 was $77.2 million, an increase of 1% from $76.8 million for 2022. There was no COVID-19 related revenue in the six months ended June 30, 2023. Ex-COVID related revenue growth for the second quarter of 2023 was 11%.
        • Cell Processing platform revenue was $37.7 million, up $7.4 million, or 24%, over the same period in 2022. Biopreservation media growth was 24%.
        • Freezers and Thaw Systems platform revenue was $26.9 million, down $7.1 million, or 21%, over the same period in 2022. Ex-COVID related revenue was down $5.9 million, or 18%, over the same period in 2022.
        • Storage and Storage Services platform revenue was $12.6 million, up $0.1 million, or 1%, over the same period in 2022. Ex-COVID related revenue growth was $6.2 million, or 96%, over the same period in 2022.

      GROSS MARGIN

      • Gross margin (GAAP) for the second quarter of 2023 was 28% compared with 33% for the second quarter of 2022. Adjusted gross margin (non-GAAP) for the second quarter of 2023 was 35% compared with 36% for the second quarter of 2022.
      • Gross margin (GAAP) for the six months ended June 30, 2023 was 32% compared with 31% for the six months ended 2022. Adjusted gross margin (non-GAAP) for the six months ended June 30, 2023 was 36% compared with 34% for the first six months ended of 2022.
      • The decrease in gross margin for the second quarter of 2023 was primarily due to increases in personnel expenses and an inventory reserve related to potentially unusable final product containers from a key supplier. The increase in gross margin for the six months ended June 30, 2023 was primarily due to a favorable product mix in our biopreservation media product line and a greater concentration of higher margin revenue as a percentage of total revenue in comparison to the same period in 2022.

      OPERATING EXPENSE

      • Operating expense (GAAP) for the second quarter of 2023 was $54.8 million compared with $117.1 million for the second quarter of 2022. Adjusted operating expense (non-GAAP) for the second quarter of 2023 was $22.2 million compared with $20.3 million for the second quarter 2022.
      • Operating expense (GAAP) for the six months ended June 30, 2023 was $106.1 million compared with $161.3 million for the six months ended 2022. Adjusted operating expense (non-GAAP) for the six months ended June 30, 2023 was $46.8 million compared with $40.4 million for 2022.
      • The decrease in GAAP operating expenses is primarily due to the $69.9 million intangible asset impairment charge that occurred in Q2 2022. The increase in non-GAAP operating expenses for the three and six months ended of June 30, 2023 was primarily due to increases in professional services fees and employee compensation costs from an increase in headcount compared to the prior year.

      OPERATING LOSS

      • Operating loss (GAAP) for the second quarter of 2023 was $15.3 million compared with $76.6 million for the second quarter of 2022. Adjusted operating loss (non-GAAP) for the second quarter of 2023 was $10.4 million compared with $5.7 million for the second quarter of 2022.
      • Operating loss (GAAP) for the six months ended June 30, 2023 was $28.9 million compared with $84.5 million for the six months ended 2022. Adjusted operating loss (non-GAAP) for the six months ended June 30, 2023 was $21.0 million compared with $14.1 million for the first six months ended of 2022.

      NET LOSS

      • Net loss (GAAP) for the second quarter of 2023 was $10.2 million compared with $72.9 million for the second quarter of 2022. Adjusted net loss (non-GAAP) for the second quarter of 2023 was $10.4 million compared with $5.8 million for the second quarter of 2022.
      • Net loss (GAAP) for the six months ended June 30, 2023 was $23.9 million compared with $80.3 million for the six months ended 2022. Adjusted net loss (non-GAAP) for the six months ended June 30, 2023 was $21.0 million compared with $14.2 million for the first six months ended of 2022.

      LOSS PER SHARE

      • Loss per share (GAAP) for the second quarter of 2023 was $0.23 compared with loss per share of $1.72 for the second quarter of 2022.
      • Loss per share (GAAP) for the six months ended June 30, 2023 was $0.55 compared with loss per share of $1.90 for the first six months ended of 2022.

      ADJUSTED EBITDA

      • Adjusted EBITDA, a non-GAAP measure, for the second quarter of 2023 was negative $1.2 million compared with $1.2 million for the second quarter of 2022.
      • Adjusted EBITDA, a non-GAAP measure, for the six months ended June 30, 2023 was negative $2.2 million compared with $44,000 for the first six months ended of 2022.

      CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES

      • Cash, cash equivalents, and marketable securities as of June 30, 2023, were $48.1 million.

      2023 Revenue Guidance

      BioLife Solutions is updating 2023 revenue guidance, which is based on expectations for its existing business.

      Total revenue for 2023 is expected to range from $144 million to $158 million, reflecting a year-over-year decrease of 11% to 2%. Excluding COVID-19-related revenue, this range reflects a year-over-year decrease of 3% to an increase of 6%.

      Expectations for 2023 total revenue include the following platform contributions:

      • Cell processing platform: $65.0 million to $74.0 million, a decrease of 5% to an increase of 8% over 2022. Previous guidance estimated revenues to be $89.0 - $93.0 million.
      • Freezers and Thaw Systems platform: $53.0 million to $56.0 million, an decrease of 21% to 16% compared to 2022. Excluding COVID-19-related revenue, year-over-year decrease of 18% to 13%. Previous guidance estimated revenues to be $72.5 - $79.0 million.
      • Storage and Storage Services platform: $26.0 million to $28.0 million, a decrease of 2% to an increase of 6% over 2022. Excluding COVID-19-related revenue, year-over-year growth of 61% to 74%. Previous guidance estimated revenues to be $26.5 - $30.0 million.

      Conference Call & Webcast

      Management will discuss the Company's financial results, provide a general business update and answer questions during a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).

      To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers or (646) 307-1963 for international callers. The conference ID number is 4014878. A webcast replay will be available approximately two hours after the call ends and will be archived on https://www.biolifesolutions.com/ for 90 days.

      About BioLife Solutions

      BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor® and HypoThermosol® biopreservation media for shipping and storage, the ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools.  For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, or www.sextonbio.com and follow BioLife on Twitter.

      Cautions Regarding Forward Looking Statements

      Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designed," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

      Non-GAAP Measures of Financial Performance:

      To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: adjusted gross profit and gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release.

      We believe these non-GAAP financial measures are useful to investors in assessing our operating performance. We use these financial measures internally to evaluate our operating performance and for planning and forecasting of future periods.  We also believe it is in the best interests of investors to provide this non-GAAP information.

      While we believe these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of these non-GAAP financial measures. These non-GAAP financial measures may not be reported by competitors, and they may not be directly comparable to similarly titled measures of other companies due to differences in calculation methodologies. The non-GAAP financial measures are not an alternative to GAAP information and are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures. They should be used only as a supplement to GAAP information and should be considered only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

      Media & Investor Relations

      At the Company
      Troy Wichterman
      Chief Financial Officer
      (425) 402-1400
      [email protected]

      Investors

      LHA Investor Relations
      Jody Cain
      (310) 691-7100
      [email protected]

      BIOLIFE SOLUTIONS, INC.

      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

      (Unaudited, amounts in thousands, except share and per share amounts)



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,

      (In thousands, except per share and share data)

      2023


      2022


      2023


      2022









      Product revenue

      $               33,037


      $               34,170


      $               64,630


      $               64,558

      Service revenue

      4,195


      3,698


      8,665


      6,787

      Rental revenue

      2,276


      2,665


      3,915


      5,407

      Total product, rental, and service revenue

      39,508


      40,533


      77,210


      76,752

      Costs and operating expenses:








      Cost of product, rental, and service revenue (exclusive of Intangible asset amortization)

      $               27,696


      $               26,194


      $               51,359


      $               50,640

      General and administrative

      15,402


      11,652


      30,241


      23,182

      Sales and marketing

      6,318


      5,415


      12,789


      10,306

      Research and development

      4,840


      3,428


      8,995


      7,209

      Intangible asset impairment charges

      —


      69,900


      —


      69,900

      Intangible asset amortization

      1,450


      2,863


      2,911


      5,725

      Acquisition costs

      —


      5


      —


      16

      Change in fair value of contingent consideration

      (918)


      (2,361)


      (198)


      (5,695)

      Total operating expenses

      54,788


      117,096


      106,097


      161,283

      Operating loss

      (15,280)


      (76,563)


      (28,887)


      (84,531)









      Other income (expense):








      Gain on settlement of Global Cooling escrow

      5,115


      —


      5,115


      —

      Interest expense

      (419)


      (32)


      (829)


      (216)

      Other income (expense)

      390


      (22)


      785


      110

      Total other income (expense), net

      5,086


      (54)


      5,071


      (106)









      Loss before income tax (expense) benefit

      (10,194)


      (76,617)


      (23,816)


      (84,637)

      Income tax (expense) benefit

      (5)


      3,739


      (97)


      4,338

      Net loss

      $             (10,199)


      $             (72,878)


      $             (23,913)


      $             (80,299)









      Net loss attributable to common shareholders:








      Basic and Diluted

      $             (10,199)


      $             (72,878)


      $             (23,913)


      $             (80,299)

      Net loss per share attributable to common shareholders:








      Basic and Diluted

      $                 (0.23)


      $                 (1.72)


      $                 (0.55)


      $                 (1.90)

      Weighted average shares used to compute loss per share attributable to common shareholders:








      Basic and Diluted

      43,441,219


      42,460,189


      43,235,558


      42,238,355

      BIOLIFE SOLUTIONS, INC.

      CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

      (Unaudited, amounts in thousands)



      Three Months Ended

      June 30,


      Six Months Ended

      June 30,

      (In thousands)

      2023


      2022


      2023


      2022









      Net loss

      $       (10,199)


      $    (72,878)


      $       (23,913)


      $       (80,299)

      Other comprehensive income (loss)

      35


      (462)


      180


      (618)

      Comprehensive loss

      $       (10,164)


      $    (73,340)


      $       (23,733)


      $       (80,917)

      BIOLIFE SOLUTIONS, INC.

      CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION

      (Unaudited, amounts in thousands)



      June 30,


      December

      (In thousands)

      2023


      2022

      Cash, cash equivalents, and marketable securities

      $         48,128


      $         64,065

      Working capital

      80,724


      93,870

      Current assets

      120,311


      138,452

      Current liabilities

      39,587


      44,582

      Total assets

      433,177


      450,229





      Long-term obligations

      41,462


      41,459

      Accumulated deficit

      (270,828)


      (246,915)

      Total shareholders' equity

      $       352,128


      $       364,188

      BIOLIFE SOLUTIONS, INC.

      CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION

      (Unaudited, amounts in thousands)



      Six Months Ended
      June 30,

      (In thousands)

      2023


      2022

      Net cash used in operating activities

      $       (10,430)


      $       (17,841)

      Net cash used in (provided by) investing activities

      12,218


      (27,340)

      Net cash used in (provided by) financing activities

      142


      (470)

      Effects of currency translation

      28


      (190)

      Net decrease (increase) in cash, cash equivalents, and restricted stock

      $           1,958


      $       (45,841)

      BIOLIFE SOLUTIONS, INC.

      RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP ADJUSTED GROSS PROFIT

      (Unaudited, amounts in thousands)



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,

      (In thousands)

      2023


      2022


      2023


      2022

      GAAP GROSS PROFIT

      $     11,079


      $     13,246


      $     24,385


      $     23,926

      GAAP GROSS MARGIN

      28 %


      33 %


      32 %


      31 %









      ADJUSTMENTS TO GROSS PROFIT:








      Inventory step-up

      —


      251


      —


      251

      Inventory reserve costs

      2,185


      —


      2,185


      —

      Intangible asset amortization

      733


      1,093


      1,466


      2,186

      ADJUSTED GROSS PROFIT

      $     13,997


      $     14,590


      $     28,036


      $     26,363

      ADJUSTED GROSS MARGIN

      35 %


      36 %


      36 %


      34 %

      BIOLIFE SOLUTIONS, INC.

      RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP ADJUSTED OPERATING EXPENSES

      (Unaudited, amounts in thousands)



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,

      (In thousands)

      2023


      2022


      2023


      2022

      GAAP OPERATING EXPENSES

      $        54,788


      $      117,096


      $      106,097


      $      161,283









      ADJUSTMENTS TO OPERATING EXPENSES:








      Cost of product, rental, and service revenue

      (27,696)


      (26,194)


      (51,359)


      (50,640)

      Inventory reserve costs

      (2,185)


      —


      (2,185)


      —

      Acquisition and divestiture costs

      (2,143)


      (5)


      (2,976)


      (16)

      Intangible asset amortization

      (1,450)


      (2,863)


      (2,911)


      (5,725)

      Loss on disposal of assets

      (19)


      (162)


      (28)


      (257)

      Change in fair value of contingent consideration

      918


      2,361


      198


      5,695

      Intangible asset impairment charges

      —


      (69,900)


      —


      (69,900)

      ADJUSTED OPERATING EXPENSES

      $        22,213


      $        20,333


      $        46,836


      $        40,440

      BIOLIFE SOLUTIONS, INC.

      RECONCILIATION OF GAAP OPERATING LOSS TO NON-GAAP ADJUSTED OPERATING LOSS

      (Unaudited, amounts in thousands)



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,

      (In thousands)

      2023


      2022


      2023


      2022

      GAAP OPERATING LOSS

      $       (15,280)


      $       (76,563)


      $       (28,887)


      $       (84,531)









      ADJUSTMENTS TO GAAP OPERATING LOSS








      Inventory step-up

      —


      251


      —


      251

      Inventory reserve costs

      2,185


      —


      2,185


      —

      Acquisition and divestiture costs

      2,143


      5


      2,976


      16

      Intangible asset amortization

      1,450


      2,863


      2,911


      5,725

      Loss on disposal of assets

      19


      162


      28


      257

      Change in fair value of contingent consideration

      (918)


      (2,361)


      (198)


      (5,695)

      Intangible asset impairment charges

      —


      69,900


      —


      69,900

      ADJUSTED OPERATING LOSS

      $       (10,401)


      $        (5,743)


      $       (20,985)


      $       (14,077)

      BIOLIFE SOLUTIONS, INC.

      RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED NET LOSS

      (Unaudited, amounts in thousands)



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,

      (In thousands)

      2023


      2022


      2023


      2022

      GAAP NET LOSS

      $       (10,199)


      $       (72,878)


      $       (23,913)


      $       (80,299)









      ADJUSTMENTS TO GAAP NET LOSS








      Inventory step-up

      —


      251


      —


      251

      Inventory reserve costs

      2,185


      —


      2,185


      —

      Acquisition and divestiture costs

      2,143


      5


      2,976


      16

      Intangible asset amortization

      1,450


      2,863


      2,911


      5,725

      Loss on disposal of assets

      19


      162


      28


      257

      Change in fair value of contingent consideration

      (918)


      (2,361)


      (198)


      (5,695)

      Income tax expense / (benefit)

      5


      (3,739)


      97


      (4,338)

      Gain on settlement of Global Cooling escrow

      (5,115)


      —


      (5,115)


      —

      Intangible asset impairment charges

      —


      69,900


      —


      69,900

      ADJUSTED NET LOSS

      $       (10,430)


      $        (5,797)


      $       (21,029)


      $       (14,183)

      BIOLIFE SOLUTIONS, INC.

      RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA

      (Unaudited, amounts in thousands)



      Three Months Ended
      June 30,


      Six Months Ended
      June 30,

      (In thousands)

      2023


      2022


      2023


      2022

      GAAP NET LOSS

      $       (10,199)


      $       (72,878)


      $       (23,913)


      $       (80,299)









      ADJUSTMENTS:








      Interest expense

      419


      32


      829


      216

      Income tax expense / (benefit)

      5


      (3,739)


      97


      (4,338)

      Depreciation

      2,003


      986


      3,733


      2,639

      Intangible asset amortization

      1,450


      2,863


      2,911


      5,725

      EBITDA

      $        (6,322)


      $       (72,736)


      $       (16,343)


      $       (76,057)









      OTHER ADJUSTMENTS:








      Share-based compensation (non-cash)

      6,856


      5,973


      14,220


      11,372

      Inventory step-up

      —


      251


      —


      251

      Inventory reserve costs

      2,185


      —


      2,185


      —

      Acquisition and divestiture costs

      2,143


      5


      2,976


      16

      Loss on disposal of assets

      19


      162


      28


      257

      Change in fair value of contingent consideration

      (918)


      (2,361)


      (198)


      (5,695)

      Gain on settlement of Global Cooling escrow

      (5,115)


      —


      (5,115)


      —

      Intangible asset impairment charges

      —


      69,900


      —


      69,900

      ADJUSTED EBITDA

      $        (1,152)


      $          1,194


      $        (2,247)


      $              44

      BIOLIFE SOLUTIONS, INC.

      RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA EXCLUDING FREEZER BUSINESS

      (Unaudited, amounts in thousands)



      Six Months Ended
      June 30, 2023

      (In thousands)

      Freezers


      Excluding Freezers


      Reported Results

      GAAP NET LOSS

      $          (12,090)


      $          (11,823)


      $          (23,913)







      Expense allocation(1)

      (3,174)


      3,174


      —

      GAAP NET LOSS AS ADJUSTED FOR EXPENSE ALLOCATION

      $          (15,264)


      $            (8,649)


      $          (23,913)







      ADJUSTMENTS:






      Interest expense

      108


      721


      829

      Income tax expense / (benefit)

      3


      94


      97

      Depreciation

      555


      3,178


      3,733

      Intangible asset amortization

      503


      2,408


      2,911

      EBITDA

      $          (14,095)


      $            (2,248)


      $          (16,343)







      OTHER ADJUSTMENTS:






      Share-based compensation (non-cash)

      3,632


      10,588


      14,220

      Acquisition and divestiture costs

      —


      2,976


      2,976

      Loss on disposal of assets

      —


      28


      28

      Change in fair value of contingent consideration

      —


      (198)


      (198)

      Gain on settlement of Global Cooling escrow

      —


      (5,115)


      (5,115)

      Inventory reserve costs

      —


      $              2,185


      $              2,185

      ADJUSTED EBITDA

      $          (10,463)


      $              8,216


      $            (2,247)



      (1)

      Expense allocations reflected here represent allocations made by the corporate entity for the benefit of the freezer business (Stirling Ultracold and Custom Biogenic Systems). These allocations were calculated using certain judgments and estimates based on information currently available, though actual results may differ from assumptions used to present this pro forma information.

      SOURCE BioLife Solutions, Inc.

      Modal title

      Also from this source

      BioLife Solutions Reports Second Quarter 2026 Financial Results

      BioLife Solutions Reports Second Quarter 2026 Financial Results

      BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the...

      BioLife Solutions Reports First Quarter 2026 Financial Results

      BioLife Solutions Reports First Quarter 2026 Financial Results

      BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Biotechnology

      Biotechnology

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.